Navigation Links
ViroPharma Augments Senior Management
Date:1/3/2008

- Company Appoints Thomas Doyle Vice President, Strategic Initiatives and Promotes Peter Wolf to Vice President, General Counsel and Secretary of the

Board of Directors -

EXTON, Pa., Jan. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that effective, January 1, 2008, Thomas F. Doyle has been appointed as vice president, strategic initiatives and J. Peter Wolf has been promoted to vice president, general counsel and secretary of the Board of Directors.

Mr. Doyle will oversee strategic planning efforts at ViroPharma including expanding exclusivity of the current product portfolio, and assist in business development activities. He will also continue leading the efforts in ViroPharma's ongoing discussions with the U.S. Food & Drug Administration regarding the company's continuing efforts to assure the safety of patients afflicted by C. difficile infection. Prior to his appointment, Mr. Doyle served as Vice President, General Counsel of ViroPharma since November 1997, as Secretary since February 1997 and as Executive Director, Counsel since joining ViroPharma in November 1996. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper, Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his B.S. in Accounting from Mt. St. Mary's College.

"Tom has been a great leader for ViroPharma for well over a decade and during that time has helped navigate the company through times of both prosperity and difficulty," commented Michel de Rosen, ViroPharma's president and chief executive officer. "Tom continues to represent well the ViroPharma values of teamwork, people, quality and courage; he has great passion for ViroPharma and his integrity is second to none. I look forward to continuing to work closely with Tom in this critical new role for ViroPharma's future."

Mr. Wolf will be responsible for the oversight of ViroPharma's legal department and serve as corporate secretary. Mr. Wolf has been ViroPharma's Associate General Counsel since April 2004. Immediately prior to joining ViroPharma, Mr. Wolf was an attorney at Pepper Hamilton LLP. Mr. Wolf received his J.D. from George Washington National Law Center. Prior to attending George Washington, Mr. Wolf received his B.A. in International Relations from the University of Delaware.

"Since joining ViroPharma in 2004, Pete has demonstrated great teamwork, sound judgment and excellent customer focus," commented de Rosen. "He has a seemingly limitless capacity for work. We are very fortunate at ViroPharma to have a highly qualified individual such as Pete already in the organization to assume and expand the role of general counsel."

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
2. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma to Present at the UBS Global Life Sciences Conference
5. ViroPharma to Present at the Maxim Group First Annual Growth Conference
6. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
7. MSC Names Paul Bode as Senior Vice President, Ancillary Sales
8. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
9. Sharps Compliance Corp. Announces New Senior Vice President of Sales and Marketing
10. Sunrise to Unveil New Residence for Seniors at Clayton on the Park
11. American Lung Association Offers Biodiesel Scholarship to Minnesota High School Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology: